Milestone Asset Management LLC increased its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU – Free Report) by 5.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 163,789 shares of the company’s stock after buying an additional 8,662 shares during the quarter. Milestone Asset Management LLC’s holdings in Caribou Biosciences were worth $260,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Erste Asset Management GmbH purchased a new position in shares of Caribou Biosciences during the third quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. grew its position in Caribou Biosciences by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after purchasing an additional 6,768 shares during the last quarter. AQR Capital Management LLC acquired a new position in Caribou Biosciences in the second quarter valued at $30,000. Intech Investment Management LLC purchased a new stake in shares of Caribou Biosciences in the third quarter valued at about $43,000. Finally, Point72 DIFC Ltd boosted its stake in shares of Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after buying an additional 23,995 shares during the period. Hedge funds and other institutional investors own 77.51% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have commented on CRBU. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Citigroup cut their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Finally, Bank of America lowered their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Caribou Biosciences currently has an average rating of “Buy” and a consensus target price of $10.33.
Caribou Biosciences Trading Down 2.2 %
Shares of CRBU stock opened at $1.31 on Friday. Caribou Biosciences, Inc. has a 12-month low of $1.30 and a 12-month high of $8.33. The company has a market cap of $118.62 million, a price-to-earnings ratio of -0.79 and a beta of 2.34. The stock has a 50 day simple moving average of $1.78 and a 200-day simple moving average of $1.98.
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. The firm had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. On average, equities analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.
Caribou Biosciences Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Featured Articles
- Five stocks we like better than Caribou Biosciences
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Following Congress Stock Trades
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Want to see what other hedge funds are holding CRBU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caribou Biosciences, Inc. (NASDAQ:CRBU – Free Report).
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.